QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

/PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered...

Related Keywords

Shanghai ,China ,Xiangdong Qu ,Jiangxi ,Shenzhen ,Guangdong ,Jian Zhang ,Hangzhou ,Zhejiang ,Lin Shen ,Jundu ,Shanxi ,San Francisco ,California ,United States ,Yuping Sun ,Viva Bio ,Xiaohua Chen ,Tao Yu ,Yanqiao Zhang ,Jie Hou ,Li Wei ,Yusheng Wang ,Qin Yu ,Jifang Gong ,Yakun Wang ,Shanghai Pudong Kechuang Group ,Qurebio Ltd ,Bocom Industrial Investment Hangzhou Equity Partnership ,Shenzhen Capital Group ,Suzhou Oriza Holdings ,Hengrui Pharmaceuticals ,Clinical Data ,Cancers Symposium ,Meeting Abstracts ,Viva Bio Innovator ,Jundu Investment ,Watson Capital ,Bocom Industrial Investment ,Equity Investment Partnership ,Zhuhai Longmen Capital Management ,Shenzhen Lihe Hongxin Venture ,Three Rivers ,Precision Scientific ,Zhangheng Road ,Pudong New Area ,